These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 37479759)
21. Identification and Validation of Pyroptosis-Related Gene Signature to Predict Prognosis and Reveal Immune Infiltration in Hepatocellular Carcinoma. Fu XW; Song CQ Front Cell Dev Biol; 2021; 9():748039. PubMed ID: 34820376 [No Abstract] [Full Text] [Related]
22. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis. Yan Z; He M; He L; Wei L; Zhang Y Front Immunol; 2021; 12():723271. PubMed ID: 34925311 [TBL] [Abstract][Full Text] [Related]
23. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma. Li R; Zhao W; Liang R; Jin C; Xiong H Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972 [No Abstract] [Full Text] [Related]
24. Identification and validation of a tyrosine metabolism-related prognostic prediction model and characterization of the tumor microenvironment infiltration in hepatocellular carcinoma. Zhou Y; Li X; Long G; Tao Y; Zhou L; Tang J Front Immunol; 2022; 13():994259. PubMed ID: 36341373 [TBL] [Abstract][Full Text] [Related]
25. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma. Liu Y; Jiang J Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878 [TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma. Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032 [TBL] [Abstract][Full Text] [Related]
27. Identification of an Epithelial-Mesenchymal Transition-Related Long Non-coding RNA Prognostic Signature to Determine the Prognosis and Drug Treatment of Hepatocellular Carcinoma Patients. Huang S; Li D; Zhuang L; Zhang J; Wu J Front Med (Lausanne); 2022; 9():850343. PubMed ID: 35685422 [TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma. Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566 [TBL] [Abstract][Full Text] [Related]
29. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma. Wang Y; Song F; Zhang X; Yang C Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359 [TBL] [Abstract][Full Text] [Related]
30. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma. Fang G; Zhang Q; Fan J; Li H; Ding Z; Fu J; Wu Y; Zeng Y; Liu J BMC Cancer; 2022 Sep; 22(1):999. PubMed ID: 36127654 [TBL] [Abstract][Full Text] [Related]
31. Prognostic Implication of a Novel Metabolism-Related Gene Signature in Hepatocellular Carcinoma. Yuan C; Yuan M; Chen M; Ouyang J; Tan W; Dai F; Yang D; Liu S; Zheng Y; Zhou C; Cheng Y Front Oncol; 2021; 11():666199. PubMed ID: 34150630 [TBL] [Abstract][Full Text] [Related]
32. Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates. Guo C; Tang Y; Yang Z; Li G; Zhang Y Front Immunol; 2022; 13():958161. PubMed ID: 36032071 [TBL] [Abstract][Full Text] [Related]
33. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma. Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904 [No Abstract] [Full Text] [Related]
34. Five metastasis-related mRNAs signature predicting the survival of patients with liver hepatocellular carcinoma. Chen C; Liu YQ; Qiu SX; Li Y; Yu NJ; Liu K; Zhong LM BMC Cancer; 2021 Jun; 21(1):693. PubMed ID: 34116652 [TBL] [Abstract][Full Text] [Related]
35. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma. Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167 [TBL] [Abstract][Full Text] [Related]
36. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy. Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206 [TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma. Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S Front Immunol; 2023; 14():1164669. PubMed ID: 37545521 [TBL] [Abstract][Full Text] [Related]
38. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns. Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675 [TBL] [Abstract][Full Text] [Related]
39. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma. Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539 [TBL] [Abstract][Full Text] [Related]
40. Prognostic model for hepatocellular carcinoma based on anoikis-related genes: immune landscape analysis and prediction of drug sensitivity. Zhang D; Liu S; Wu Q; Ma Y; Zhou S; Liu Z; Sun W; Lu Z Front Med (Lausanne); 2023; 10():1232814. PubMed ID: 37502362 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]